Source: Medpick
  • Avisa Diagnostics (AVBT)  intends to raise approximately C$375,000 from a non-brokered private placement
  • The company will issue 1.39 million shares to an eligible purchaser outside of Canada and the US
  • Avisa Diagnostic is a clinical-stage medical device company developing the Avisa BreathTest™
  • Avisa Diagnostics Inc. (AVBT) is unchanged, trading at $0.30 per share at 4 pm ET

Avisa Diagnostics (AVBT)  intends to conduct a non-brokered private placement of 1,390,000 common shares to raise approximately C$375,000.

The offering is expected to close on or about July 15.

Avisa intends to use the net proceeds from the offering for operations and expansion of its business and for general working capital purposes.

The offering is being made to an eligible purchaser resident in a jurisdiction other than Canada and the United States. The shares will not be subject to resale restrictions in Canada.

Avisa Diagnostic is a clinical-stage medical device company developing the Avisa BreathTest™, a novel drug/device biomarker technology platform.

Avisa Diagnostics Inc. (AVBT) is unchanged, trading at $0.30 per share at 4 pm ET.

More From The Market Online

Telo Genomics and Emery Pharma collaborate

Telo Genomics (TSXV:TELO) collaborates with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.